Immunic Starts Enrollment in Phase 2 CALDOSE-1 Clinical Trial

Immunic Starts Enrollment in Phase 2 CALDOSE-1 Clinical Trial
The first patient has enrolled in the CALDOSE-1 phase 2 clinical trial, which seeks to determine whether Immunic AG's investigational drug IMU-838 can induce and maintain remission in patients with active ulcerative colitis (UC). The first sites for the trial are in the United States, and recruitment of participants is already underway across multiple U.S. sites. The primary goal of the CALDOSE-1 trial (NCT03341962) is to demonstrate the clinical efficacy of multiple doses of IMU-838 or placebo to induce remission in patients with active UC. Th
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *